Hims & Hers has expanded beyond its core telehealth business through geographic expansion into the UK and Canada, new product launches, and strategic acquisitions. However, the company faces significant challenges from a Novo Nordisk lawsuit over compounded semaglutide products and DOJ scrutiny, which could impact future growth and compliance efforts.
Cyborg Score Rationale
Hims & Hers faces severe headwinds affecting its financial outlook due to legal battles and regulatory scrutiny. The company has halted its compounded semaglutide pill offering following FDA focus on non-approved GLP-1 drugs. Multiple analyst downgrades reflect uncertain recovery prospects.
Top Insights
Stock declined 29.2% following the Novo Nordisk lawsuit over compounded semaglutide products.
TD Cowen reduced its price target to $20, signaling caution over ongoing investigations.
Company launched Labs testing experience offering blood-based biomarker testing and doctor-developed action plans.
Last quarter revenue reached $598.98M with next quarter expected to reach $619.20M.
Named Competitors
Wegovy — FDA-approved GLP-1 weight loss injection and oral pill
CVS Health — Integrated pharmacy and telehealth services
Costco — Retail pharmacy and wellness services
GoodRx — Pharmacy discount and digital health platform
Recent Developments
(February 2026) FDA head warns against illegal copycat drugs; DOJ referral announced
(February 2026) Novo Nordisk lawsuit filed; multiple analyst downgrades follow
(January 2026) Company stops selling Wegovy compounded semaglutide pills
(December 2025) Expanded Weight Loss Program to UK; acquired Canadian platform Livewell
Open the full interactive Hims & Hers Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.